203 related articles for article (PubMed ID: 22796139)
1. Development of VAX128, a recombinant hemagglutinin (HA) influenza-flagellin fusion vaccine with improved safety and immune response.
Taylor DN; Treanor JJ; Sheldon EA; Johnson C; Umlauf S; Song L; Kavita U; Liu G; Tussey L; Ozer K; Hofstaetter T; Shaw A
Vaccine; 2012 Aug; 30(39):5761-9. PubMed ID: 22796139
[TBL] [Abstract][Full Text] [Related]
2. Induction of a potent immune response in the elderly using the TLR-5 agonist, flagellin, with a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125, STF2.HA1 SI).
Taylor DN; Treanor JJ; Strout C; Johnson C; Fitzgerald T; Kavita U; Ozer K; Tussey L; Shaw A
Vaccine; 2011 Jul; 29(31):4897-902. PubMed ID: 21596084
[TBL] [Abstract][Full Text] [Related]
3. Safety and immunogenicity of a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125) in healthy young adults.
Treanor JJ; Taylor DN; Tussey L; Hay C; Nolan C; Fitzgerald T; Liu G; Kavita U; Song L; Dark I; Shaw A
Vaccine; 2010 Dec; 28(52):8268-74. PubMed ID: 20969925
[TBL] [Abstract][Full Text] [Related]
4. Flagellin-HA vaccines protect ferrets and mice against H5N1 highly pathogenic avian influenza virus (HPAIV) infections.
Liu G; Song L; Reiserova L; Trivedi U; Li H; Liu X; Noah D; Hou F; Weaver B; Tussey L
Vaccine; 2012 Nov; 30(48):6833-8. PubMed ID: 23000130
[TBL] [Abstract][Full Text] [Related]
5. A randomized clinical trial to identify the optimal antigen and MF59(®) adjuvant dose of a monovalent A/H1N1 pandemic influenza vaccine in healthy adult and elderly subjects.
Hatz C; von Sonnenburg F; Casula D; Lattanzi M; Leroux-Roels G
Vaccine; 2012 May; 30(23):3470-7. PubMed ID: 22446638
[TBL] [Abstract][Full Text] [Related]
6. A phase I randomized, double-blind, controlled trial of 2009 influenza A (H1N1) inactivated monovalent vaccines with different adjuvant systems.
Precioso AR; Miraglia JL; Campos LM; Goulart AC; Timenetsky Mdo C; Cardoso MR; Luna E; Mondini G; Guedes Jda S; Raw I
Vaccine; 2011 Nov; 29(48):8974-81. PubMed ID: 21945258
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of safety and immunogenicity of recombinant influenza hemagglutinin (H5/Indonesia/05/2005) formulated with and without a stable oil-in-water emulsion containing glucopyranosyl-lipid A (SE+GLA) adjuvant.
Treanor JJ; Essink B; Hull S; Reed S; Izikson R; Patriarca P; Goldenthal KL; Kohberger R; Dunkle LM
Vaccine; 2013 Nov; 31(48):5760-5. PubMed ID: 24075920
[TBL] [Abstract][Full Text] [Related]
8. A clinical study to assess the immunogenicity and safety of a monovalent 2009 influenza A (H1N1) vaccine in an area with low-level epidemics of pandemic influenza.
Kung HC; Huang KC; Kao TM; Lee YC; Chang FY; Wang NC; Liu YC; Lee WS; Liu HJ; Chen CI; Chen CH; Huang LM; Hsieh SM
Vaccine; 2010 Oct; 28(45):7337-43. PubMed ID: 20817013
[TBL] [Abstract][Full Text] [Related]
9. Safety and immunogenicity of a recombinant M2e-flagellin influenza vaccine (STF2.4xM2e) in healthy adults.
Turley CB; Rupp RE; Johnson C; Taylor DN; Wolfson J; Tussey L; Kavita U; Stanberry L; Shaw A
Vaccine; 2011 Jul; 29(32):5145-52. PubMed ID: 21624416
[TBL] [Abstract][Full Text] [Related]
10. A randomised, single-blind, dose-range study to assess the immunogenicity and safety of a cell-culture-derived A/H1N1 influenza vaccine in adult and elderly populations.
Hatz C; Cramer JP; Vertruyen A; Schwarz TF; von Sonnenburg F; Borkowski A; Lattanzi M; Hilbert AK; Cioppa GD; Leroux-Roels G
Vaccine; 2012 Jul; 30(32):4820-7. PubMed ID: 22626675
[TBL] [Abstract][Full Text] [Related]
11. Pre-vaccination immunity and immune responses to a cell culture-derived whole-virus H1N1 vaccine are similar to a seasonal influenza vaccine.
Ehrlich HJ; Müller M; Kollaritsch H; Pinl F; Schmitt B; Zeitlinger M; Loew-Baselli A; Kreil TR; Kistner O; Portsmouth D; Fritsch S; Maritsch F; Aichinger G; Pavlova BG; Barrett PN
Vaccine; 2012 Jun; 30(30):4543-51. PubMed ID: 22475864
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial.
Roman F; Vaman T; Gerlach B; Markendorf A; Gillard P; Devaster JM
Vaccine; 2010 Feb; 28(7):1740-5. PubMed ID: 20034605
[TBL] [Abstract][Full Text] [Related]
13. Influenza A (H1N1) 2009 two-dose immunization of US children: an observer-blinded, randomized, placebo-controlled trial.
Plennevaux E; Blatter M; Cornish MJ; Go K; Kirby D; Wali M; Reeves-Hoché MK; Denis M
Vaccine; 2011 Feb; 29(8):1569-75. PubMed ID: 21219979
[TBL] [Abstract][Full Text] [Related]
14. Dose sparing intradermal trivalent influenza (2010/2011) vaccination overcomes reduced immunogenicity of the 2009 H1N1 strain.
Hung IF; Levin Y; To KK; Chan KH; Zhang AJ; Li P; Li C; Xu T; Wong TY; Yuen KY
Vaccine; 2012 Oct; 30(45):6427-35. PubMed ID: 22910287
[TBL] [Abstract][Full Text] [Related]
15. Safety and immunogenicity of a plant-produced recombinant monomer hemagglutinin-based influenza vaccine derived from influenza A (H1N1)pdm09 virus: a Phase 1 dose-escalation study in healthy adults.
Cummings JF; Guerrero ML; Moon JE; Waterman P; Nielsen RK; Jefferson S; Gross FL; Hancock K; Katz JM; Yusibov V;
Vaccine; 2014 Apr; 32(19):2251-9. PubMed ID: 24126211
[TBL] [Abstract][Full Text] [Related]
16. Assessment of the immunogenicity and safety of varying doses of an MF59®-adjuvanted cell culture-derived A/H1N1 pandemic influenza vaccine in Japanese paediatric, adult and elderly subjects.
Fukase H; Furuie H; Yasuda Y; Komatsu R; Matsushita K; Minami T; Suehiro Y; Yotsuyanagi H; Kusadokoro H; Sawata H; Nakura N; Lattanzi M
Vaccine; 2012 Jul; 30(33):5030-7. PubMed ID: 22472791
[TBL] [Abstract][Full Text] [Related]
17. Safety and immunogenicity of adjuvanted inactivated split-virion and whole-virion influenza A (H5N1) vaccines in children: a phase I-II randomized trial.
Wu J; Liu SZ; Dong SS; Dong XP; Zhang WL; Lu M; Li CG; Zhou JC; Fang HH; Liu Y; Liu LY; Qiu YZ; Gao Q; Zhang XM; Chen JT; Zhong X; Yin WD; Feng ZJ
Vaccine; 2010 Aug; 28(38):6221-7. PubMed ID: 20638454
[TBL] [Abstract][Full Text] [Related]
18. Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine in a blinded, randomized, placebo-controlled trial of adults in Mexico.
López-Macías C; Ferat-Osorio E; Tenorio-Calvo A; Isibasi A; Talavera J; Arteaga-Ruiz O; Arriaga-Pizano L; Hickman SP; Allende M; Lenhard K; Pincus S; Connolly K; Raghunandan R; Smith G; Glenn G
Vaccine; 2011 Oct; 29(44):7826-34. PubMed ID: 21816199
[TBL] [Abstract][Full Text] [Related]
19. Safety and immunogenicity of an influenza vaccine A/H5N1 (A/Vietnam/1194/2004) when coadministered with a heat-labile enterotoxin (LT) adjuvant patch.
Glenn GM; Thomas DN; Poffenberger KL; Flyer DC; Ellingsworth LR; Andersen BH; Frech SA
Vaccine; 2009 Dec; 27 Suppl 6():G60-6. PubMed ID: 20006142
[TBL] [Abstract][Full Text] [Related]
20. Poor immune response to a standard single dose non-adjuvanted vaccination against 2009 pandemic H1N1 influenza virus A in the adult and elder hemodialysis patients.
Chang YT; Guo CY; Tsai MS; Cheng YY; Lin MT; Chen CH; Shen D; Wang JR; Sung JM
Vaccine; 2012 Jul; 30(33):5009-18. PubMed ID: 22658967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
